Results 81 to 90 of about 66,826 (280)

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis

Качественная клиническая практика, 2020
Rationale. Rheumatoid arthritis (RA) and systemic juvenile arthritis (sJA) are the most frequent rheumatic diseases in adults and adolescents, consequently. Biologics disease modifying antirheumatic drugs (bDMARDs) are eff ective in treatment of RA and s
A. S. Kolbin, A. A. Kurylev, S. A. Mishinova, Yu. E. Balykina, M. A. Proskurin   +4 more
doaj   +1 more source

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [PDF]

, 2017
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy,
Argüelles Arias, Federico, Castro Laria, Luisa, Guerra Veloz, María Fernanda, Maldonado Pérez, Belén, Merino Bohórquez, Vicente, Perea Amarillo, Raúl, Romero Gómez, Manuel, Vilches Arenas, Ángel   +7 more
core  

The decline of 6‐thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease

British Journal of Clinical Pharmacology, EarlyView.
Background Thiopurines are used to maintain remission in inflammatory bowel disease (IBD). These drugs are metabolized into 6‐thioguanine nucleotides (6‐TGN), associated with efficacy, and 6‐methylmercaptopurine ribonucleotides (6‐MMPR), associated with adverse drug reactions. Pregnancy has been linked to a shift in thiopurine metabolism, characterized
Dianne G. Bouwknegt, Paola Mian, Femke Groen, Denise van den Berg‐Zuiddam, Andrea E. van der Meulen, Femke Crouwel, Nanne K. de Boer, Debbie S. Deben, Dennis R. Wong, Luc J. J. Derijks, Gerard Dijkstra, Arno R. Bourgonje, C. Janneke van der Woude, Marijn C. Visschedijk   +13 more
wiley   +1 more source

Clinical performance of an infliximab rapid quantification assay [PDF]

, 2017
Background: Therapeutic drug monitoring (TDM)-based algorithms can be used to guide infliximab (IFX) adjustments in inflammatory bowel disease (IBD) patients.
Afonso, Joana, Andrade, Patrícia, Caldeira, Paulo, Carneiro, Fátima, Carvalho, Diana, Coelho, Rosa, Dias, Cláudia Camila, Geboes, Karel, Gonçalves, Ana Rita, Gonçalves, Raquel, Lago, Paula, Lopes, Joanne, Lopes, Susana, Magro, Fernando, Meira, Tania, Ministro, Paula, Ramos, Jaime, Rosa, Isadora, Soares, João-Bruno, Sousa, Helena Tavares, Sousa, Paula, Vieira, Ana Isabel   +21 more
core   +2 more sources

Sequential, chromosome‐specific glutamine synthetase double knockout with Cas‐CLOVER establishes enhanced CHO platforms for cell line development

Biotechnology Progress, EarlyView.
This study established the first creation of a commercially available double GS knockout (DKO) from a single KO in CHO‐K1 cells, called CleanCut GS CHO using Cas‐CLOVER. When combined with the Harbor‐IN transposase system, CleanCut GS CHO cells demonstrated a highly antibody productivity.
Cintia Gomez Limia, Valeriya Steffey, Hsueh Che Cheng, Daniel Machado, Thomas Hart, Mark Cameron McHargue, Corey Brizzee, Jack Crawford   +7 more
wiley   +1 more source

Qualification and Application of a Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometric Method for the Determination of Adalimumab in Rat Plasma

Pharmaceutics, 2018
A liquid chromatography–quadrupole time-of-flight (Q-TOF) mass spectrometric method was developed for early-stage research on adalimumab in rats. The method consisted of immunoprecipitation followed by tryptic digestion for sample preparation and ...
Yuri Park, Nahye Kim, Jangmi Choi, Min-Ho Park, Byeong ill Lee, Seok-Ho Shin, Jin-Ju Byeon, Young G. Shin   +7 more
doaj   +1 more source

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

Pharmacology Research & Perspectives, 2020
FKB327 was approved by the European Medicines Agency as a biosimilar to European‐authorized adalimumab (Humira®; AbbVie Inc). Adalimumab is a monoclonal antibody, binding and inhibiting tumor necrosis factor (TNF)‐α with use indicated for several immune ...
Stefan Schreiber, Katsuhiko Yamamoto, Rafael Muniz, Takafumi Iwura   +3 more
doaj   +1 more source